Xencor, Inc Increase (Decrease) in Contract with Customer, Liability
Xencor, Inc (XNCR) reported Increase (Decrease) in Contract with Customer, Liability of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2026-02-25
- Xencor, Inc increase (decrease) in contract with customer, liability for the quarter ending 2024-12-31 was $0.00.
- Xencor, Inc increase (decrease) in contract with customer, liability for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- Xencor, Inc increase (decrease) in contract with customer, liability for the quarter ending 2024-06-30 was $0.00.
- Xencor, Inc increase (decrease) in contract with customer, liability for the quarter ending 2024-03-31 was $0.00.
- Xencor, Inc increase (decrease) in contract with customer, liability for fiscal 2025 was $0.00.
- Xencor, Inc increase (decrease) in contract with customer, liability for fiscal 2024 was $0.00.
- Xencor, Inc increase (decrease) in contract with customer, liability for fiscal 2023 was -$30.32M.
- Xencor, Inc increase (decrease) in contract with customer, liability for fiscal 2022 was -$6.97M.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-25 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q/A 9 month · filed 2026-02-25 | $0.00 derived: sum of 2 quarters · filed 2026-02-25 | $0.00 derived: sum of 3 quarters · filed 2026-02-25 | $0.00 10-K · filed 2026-02-25 |
| 2024-09-30 | $0.00 derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2025-02-24 | $0.00 derived: sum of 2 quarters · filed 2025-02-24 | $0.00 10-Q/A · filed 2025-02-24 | -$9.22M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $0.00 derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2025-02-24 | $0.00 10-Q/A · filed 2025-02-24 | -$9.22M derived: sum of 3 quarters · filed 2026-02-25 | -$7.87M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $0.00 10-Q/A · filed 2025-02-24 | -$9.22M derived: sum of 2 quarters · filed 2026-02-25 | -$7.87M derived: sum of 3 quarters · filed 2026-02-25 | -$30.10M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | -$9.22M derived: 10-K 12 month − 10-Q/A 9 month · filed 2026-02-25 | -$7.87M derived: sum of 2 quarters · filed 2026-02-25 | -$30.10M derived: sum of 3 quarters · filed 2026-02-25 | -$30.32M 10-K · filed 2026-02-25 |
| 2023-09-30 | $1.36M derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2025-02-24 | -$20.88M derived: sum of 2 quarters · filed 2025-02-24 | -$21.10M 10-Q/A · filed 2025-02-24 | -$25.96M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | -$22.24M derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2025-02-24 | -$22.45M 10-Q/A · filed 2025-02-24 | -$27.32M derived: sum of 3 quarters · filed 2025-02-27 | -$27.43M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | -$216.00K 10-Q/A · filed 2025-02-24 | -$5.08M derived: sum of 2 quarters · filed 2025-02-27 | -$5.20M derived: sum of 3 quarters · filed 2025-02-27 | -$5.38M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | -$4.87M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$4.98M derived: sum of 2 quarters · filed 2025-02-27 | -$5.17M derived: sum of 3 quarters · filed 2025-02-27 | -$6.97M 10-K · filed 2025-02-27 |
| 2022-09-30 | -$113.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$302.00K derived: sum of 2 quarters · filed 2023-11-08 | -$2.11M 10-Q · filed 2023-11-08 | $22.24M derived: sum of 4 quarters · filed 2025-02-24 |
| 2022-06-30 | -$189.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$2.00M 10-Q · filed 2023-08-03 | $22.35M derived: sum of 3 quarters · filed 2025-02-24 | $16.10M derived: sum of 4 quarters · filed 2025-02-24 |
| 2022-03-31 | -$1.81M 10-Q · filed 2023-05-08 | $22.54M derived: sum of 2 quarters · filed 2025-02-24 | $16.29M derived: sum of 3 quarters · filed 2025-02-24 | -$42.33M derived: sum of 4 quarters · filed 2025-02-24 |
| 2021-12-31 | $24.34M derived: 10-K/A 12 month − 10-Q 9 month · filed 2025-02-24 | $18.09M derived: sum of 2 quarters · filed 2025-02-24 | -$40.53M derived: sum of 3 quarters · filed 2025-02-24 | -$55.32M 10-K/A · filed 2025-02-24 |
| 2021-09-30 | -$6.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | -$64.87M derived: sum of 2 quarters · filed 2022-11-07 | -$79.67M 10-Q · filed 2022-11-07 | -$30.89M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | -$58.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | -$73.42M 10-Q · filed 2022-08-03 | -$24.64M derived: sum of 3 quarters · filed 2023-02-27 | -$25.48M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | -$14.79M 10-Q · filed 2022-05-05 | $33.98M derived: sum of 2 quarters · filed 2023-02-27 | $33.14M derived: sum of 3 quarters · filed 2023-02-27 | $31.64M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $48.77M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $47.93M derived: sum of 2 quarters · filed 2023-02-27 | $46.44M derived: sum of 3 quarters · filed 2023-02-27 | $45.48M 10-K · filed 2023-02-27 |
| 2020-09-30 | -$845.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | -$2.34M derived: sum of 2 quarters · filed 2021-11-08 | -$3.29M 10-Q · filed 2021-11-08 | -$4.35M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | -$1.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | -$2.45M 10-Q · filed 2021-08-04 | -$3.51M derived: sum of 3 quarters · filed 2022-02-24 | -$4.09M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | -$955.00K 10-Q · filed 2021-05-05 | -$2.02M derived: sum of 2 quarters · filed 2022-02-24 | -$2.60M derived: sum of 3 quarters · filed 2022-02-24 | -$16.96M derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | -$1.06M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | -$1.65M derived: sum of 2 quarters · filed 2022-02-24 | -$16.01M derived: sum of 3 quarters · filed 2022-02-24 | $7.05M 10-K · filed 2022-02-24 |
| 2019-09-30 | -$586.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | -$14.95M derived: sum of 2 quarters · filed 2020-11-06 | $8.11M 10-Q · filed 2020-11-06 | $8.11M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-06-30 | -$14.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $8.70M 10-Q · filed 2020-08-05 | $8.70M derived: sum of 3 quarters · filed 2021-02-24 | |
| 2019-03-31 | $23.06M 10-Q · filed 2020-05-08 | $23.06M derived: sum of 2 quarters · filed 2021-02-24 | ||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | -$20.04M 10-K · filed 2021-02-24 | ||
| 2018-09-30 | -$20.04M 10-Q · filed 2019-11-05 | |||
| 2017-12-31 | -$20.05M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | -$19.35M 10-K · filed 2020-02-25 | ||
| 2017-09-30 | $700.00K 10-Q · filed 2018-11-05 | |||
| 2016-12-31 | $48.82M 10-K · filed 2019-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |